Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes-Reference-Cited by-同舟云学术

Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes

Published:2018-12-07 Issue: Volume: Page:525-537
ISSN:
Container-title:Predictive Biomarkers in Oncology
language:
Short-container-title:

Author:

Heinmöller Petra,Bänfer Gudrun,Grzelinski Marius,Alexander Katya Victoria,Alexander Kathrina A.,Jasani Bharat

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-95228-4_48

Reference35 articles.

1. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98.

2. Taylor CR. Predictive biomarkers and companion diagnostics. The future of immunohistochemistry – ‘in situ proteomics’, or just a ‘stain’? Appl Immunohistochem Mol Morphol. 2014;22(8):555–61.

3. Jørgensen JT. Companion and complementary diagnostics: clinical and regulatory perspectives. Trends Cancer. 2016;2:706–12.

4. Scheerens H, Malong A, Bassett K, Boyd Z, GuptaV, Harris J, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin Transl Sci. 2017;10:84–92.

5. Siegel J. Department of health & human services. 1998. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/trasgen092598L.pdf .

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory Errors and Their Effects on Quality Management;2022 IEEE International Conference on Industrial Engineering and Engineering Management (IEEM);2022-12-07

2. Role of Pathologist in Precision Cancer Diagnosis;Precision Cancer Medicine;2021